Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases

Human Pathology

Volumn 38, Issue 10, 2007, Pages 1489-1495

  Rioux Leclercq, Nathalie ^a,b   Fergelot, Patricia ^b,c   Zerrouki, Salim ^c   Leray, Emmanuelle ^c   Jouan, Florence ^b   Bellaud, Pascale ^a   Epstein, Jonathan I ^e   Patard, Jean Jacques ^b,d  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Rennes University   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Immunohistochemistry; Necrosis; Platelets; Prognostic factors; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor

Indexed keywords

TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; NEOVASCULARIZATION (PATHOLOGY); NEPHRECTOMY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; THROMBOCYTE COUNT; TISSUE SECTION; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548680964     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.02.014     Document Type: Article

References (51)

1. Cohen H.T., and McGovern F.J. Renal cell carcinoma. N Engl J Med 353 (2005) 2477-2490
2. Janzen N.K., Kim H.L., Figlin R.A., and Belldegrun A.S. Surveillance after radical or partial nephrectomy for localised renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
3. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 (2005) 10-30
4. Lam J.S., Shvarts O., Leppert J.T., Figlin R.A., and Belldegrun A.S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (2005) 1853-1862
5. Na X., Wu G., Ryan C.K., Schoen S.R., DiSantagnese P.A., and Messing E.M. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinoma. J Urol 170 (2003) 588-592
6. Bensalah K., Leray E., Fergelot P., et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175 (2005) 813-814
7. Latif F., Tory K., Gnara J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
8. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF-signaling enforces tumor vessel regression by interfering with pericytes-mediated endothelial cell survival mechanisms. FASEB J 18 (2004) 338-340
9. Hemmerlein B., Kugler A., Ozisik R., Ringert R.H., Radzun H.J., and Thelen P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 439 (2001) 645-652
10. Akiri G., Nahari D., Finkelstein Y., Le S.Y., Elroy-Stein O., and Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17 (1998) 227-236
11. Bornes S., Boulard M., Hieblot C., et al. Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences. J Biol Chem 279 (2004) 18717-18726
12. Huez I., Bornes S., Bresson D., Creancier L., and Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15 (2001) 2197-2210
13. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267 (1992) 26031-26037
14. Ferrara N., Houck K.A., Jakeman L.B., Winer J., and Leung D.W. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47 (1991) 211-218
15. Fuhrman S., Lasky L., and Lumas C. Prognostic significance of morphologic parameters in renal cell carcinomas. Am J Surg Pathol 6 (1982) 655-663
16. Sobin L.H., and Wittekind C. International Union against Cancer (IUCC). TNM classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York 193-195
17. Adams J., Carder P.J., Downey S., et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of Tamoxifen. Cancer Res 60 (2000) 2898-2905
18. Wu Y., Saldana L., Chillar R., and Vadgama J.V. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer postsurgery and during adjuvant treatment. Int J Oncol 20 (2002) 509-516
19. Matsumoto K., Suzuki K., Koike H., et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 23 (2003) 4953-4958
20. Yang C., Chu K., and Yeh W. Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 17 (2003) 85-89
21. Rosenbaum-Dekel Y., Fuchs A., Yakirevich E., et al. Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis. Biochem Biophys Res Commun 332 (2005) 271-278
22. Benjamin L.E., Golijanin D., Itin A., et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 (1999) 159-165
23. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
24. Ruegg C., Meuwly J.Y., Driscoll R., Werffeli P., Zaman K., and Stupp R. The quest surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 3 (2003) 673-691
25. Watanabe Y., Lee S.W., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14 (1997) 2025-2032
26. Cressey R., Wattananupong O., Lertprasertsuke N., and Vinitketkumnuen U. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumorigenesis. BMC Cancer 5 (2005) 1-8
27. Cohen T., Gitay-Goren H., Sharon R., et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfate for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270 (1995) 11322-11326
28. Park J.E., Keller G.A., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4 (1993) 1317-1326
29. Jacobsen J., Grankvist K., Rasmuson T., and Ljunberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 97 (2006) 1102-1108
30. Jacobsen J., Grankvist K., Rasmuson T., Bergh A., Landberg G., and Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93 (2004) 297-302
31. Keyt B.A., Berleau L.T., Nguyen H.V., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271 (1996) 7788-7795
32. Plouet J., Moro F., Bertagnolli S., et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272 (1997) 13390-13396
33. Sato K., Tsuchiiya N., Sasaki R., et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer 90 (1999) 874-879
34. Grunstein J., Masbad J.J., Hickey R., Giordano F., and Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 20 (2000) 7282-7291
35. Lang K.J.D., Kappel A., and Goodall G.J. Hypoxia-inducible factor-1α mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13 (2002) 1792-1801
36. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
37. Leppert J.T., Lam J.S., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 96 (2005) 281-285
38. Edwards J.G., Swinson D.E., Jones J.L., Muller S., Waller D.A., and O'Byrne K.J. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124 (2003) 1916-1923
39. Cvetkovic D., Movsas B., Dicker A.P., et al. Increased hypoxia correlate with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 57 (2001) 821-883
40. Fang J., Yan L., Shing Y., and Moses M.A. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 61 (2001) 5731-5735
41. Krupski T., Harding M.A., Herce M.E., et al. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 18 (2001) 287-302
42. Moch H., Gasser T., Amin M.B., Torhorst J., Sauter G., and Mihatsch M.J. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89 (2000) 604-614
43. Sengupta S., Lohse C.M., Leibovich B.C., et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104 (2005) 511-520
44. Brinker D.A., Amin M.B., de Peralta-Venturina M., Reuter V., Chan D.Y., and Epstein J.I. Extensively necrotic cystic renal cell carcinoma: a clinicopathological study with comparison to other cystic and necrotic renal cancers. Am J Surg Pathol 24 (2000) 988-995
45. Jacobsen J., Rasmuson T., Grankvist K., and Ljungberg B. Vascular endothelial growth factor in renal cell carcinoma. J Urol 163 (2000) 343-347
46. Kondo S., Asano M., Matsuo K., Ohmori I., and Suzuki H. Vascular endothelial growth factor/vascular permeability factor detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 31 (1994) 211-214
47. Han H., Silverman J., Santucci T., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8 (2001) 72-79
48. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med 48 (2001) 43-47
49. Oehler M.K., and Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20 (2000) 5109-5112
50. Slaton J., Inoue K., Perrotte P., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735-743
51. Edgren M., Lennernas B., Larson A., and Kalkner K.M. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res 21 (2001) 1423-1430